We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) under the European Medicines Agency (“EMA”) has given a positive opinion recommending marketing authorisation of Ozempic (semaglutide) for the treatment of adults with type II diabetes mellitus.
Semaglutide is a once-daily pre-filled pen to improve glycaemic control in type II diabetes patients. The indication also refers to specific sections of the label for study results with respect to combination with other diabetes medications, effects on glycaemic control, cardiovascular events and the populations studied.
The label also demonstrates that people with type II diabetes, who are treated with once-weekly semaglutide experienced statistically significant and sustained blood glucose control compared with Merck’s (MRK - Free Report) Januvia (sitagliptin), Astrazeneca’s (AZN - Free Report) once-weekly Bydureon (exenatide extended-release), Sanofi’s (SNY - Free Report) Lantus (insulin glargine) and placebo.
Novo Nordisk plans to conduct post-approval safety studies including a long-term diabetic retinopathy outcome study in order to get semaglutide approved in Europe. Also, the company expects to receive final marketing authorization from the European Commission in the first quarter of 2018.
We remind investors that in December, the FDA approved its semaglutide once-daily pre-filled pen to improve glycaemic control in type II diabetes patients.
Shares of the company have rallied 46.5% compared with the industry’s gain of 17.2% on a year-to-date basis.
Additionally, Novo Nordisk is making efforts to develop new treatments for diabetes, which is its core area of expertise. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp. Other than semaglutide, Novo Nordisk key pipeline candidate includes nonacog beta pegol.
GLP-1 market, which includes Lilly’s Trulicity and AstraZeneca Plc's once-weekly Bydureon might be a tough competition to Novo Nordisk’s semaglutide.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion
Novo Nordisk (NVO - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) under the European Medicines Agency (“EMA”) has given a positive opinion recommending marketing authorisation of Ozempic (semaglutide) for the treatment of adults with type II diabetes mellitus.
Semaglutide is a once-daily pre-filled pen to improve glycaemic control in type II diabetes patients. The indication also refers to specific sections of the label for study results with respect to combination with other diabetes medications, effects on glycaemic control, cardiovascular events and the populations studied.
The label also demonstrates that people with type II diabetes, who are treated with once-weekly semaglutide experienced statistically significant and sustained blood glucose control compared with Merck’s (MRK - Free Report) Januvia (sitagliptin), Astrazeneca’s (AZN - Free Report) once-weekly Bydureon (exenatide extended-release), Sanofi’s (SNY - Free Report) Lantus (insulin glargine) and placebo.
Novo Nordisk plans to conduct post-approval safety studies including a long-term diabetic retinopathy outcome study in order to get semaglutide approved in Europe. Also, the company expects to receive final marketing authorization from the European Commission in the first quarter of 2018.
We remind investors that in December, the FDA approved its semaglutide once-daily pre-filled pen to improve glycaemic control in type II diabetes patients.
Shares of the company have rallied 46.5% compared with the industry’s gain of 17.2% on a year-to-date basis.
Additionally, Novo Nordisk is making efforts to develop new treatments for diabetes, which is its core area of expertise. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp. Other than semaglutide, Novo Nordisk key pipeline candidate includes nonacog beta pegol.
GLP-1 market, which includes Lilly’s Trulicity and AstraZeneca Plc's once-weekly Bydureon might be a tough competition to Novo Nordisk’s semaglutide.
Novo Nordisk A/S Price
Novo Nordisk A/S Price | Novo Nordisk A/S Quote
Zacks Rank
Novo Nordisk carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>